Indian J Sex Transm Dis Indian J Sex Transm Dis
Official Publication of the Indian Association for the Study of Sexually Transmitted Diseases
Indian J Sex Transm Dis
The Journal | Search | Ahead Of Print | Current Issue | Archives | Instructions | Subscribe | Login    Users online: 104   Home Email this page Print this page Bookmark this page Decrease font size Default font size Increase font size

Year : 2009  |  Volume : 30  |  Issue : 1  |  Page : 51-52

Human papillomavirus vaccine

Department of Skin and V.D, Medical College and SSG Hospital, Vadodara, India

Date of Web Publication5-Sep-2009

Correspondence Address:
Y S Marfatia
Department of Skin and V.D, Medical College and SSG Hospital, Vadodara
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions


How to cite this article:
Singhal P, Marfatia Y S. Human papillomavirus vaccine. Indian J Sex Transm Dis 2009;30:51-2

How to cite this URL:
Singhal P, Marfatia Y S. Human papillomavirus vaccine. Indian J Sex Transm Dis [serial online] 2009 [cited 2020 Aug 14];30:51-2. Available from:

   New HPV Vaccine Under Study Top

A new vaccine against nine of the most harmful strains of human papillomavirus (HPV) is under study at the Medical College of Georgia. The vaccine, called nine-valent, is being compared with Gardasil, a quadrivalent vaccine already in the market that works against the two most deadly HPV types. Gardasil, approved by the U.S. Food and Drug Administration in 2006, protects against HPV types 16 and 18, which cause about 70% of HPV-related cervical cancer cases, and types 6 and 11, which cause about 90% of genital wart cases. The new drug could prevent infection from those four types and five other cancer-causing types. Like Gardasil, the new vaccine contains proteins that form virus-like particles that assemble into a hollow sphere resembling HPV's protective coating. Since the sphere lacks the actual viral DNA on the inside, it cannot cause HPV, but the body is tricked into making antibodies to protect against the real thing.

ScienceDaily (Nov. 20, 2007) - A new vaccine against nine of the most harmful strains of human papillomavirus is under study at the Medical College of Georgia. file:///E:/New%20HPV%20Vaccine%20Under%20Study.htm

   Vaccine Promising in Mice Top

According to researchers the new HPV vaccine might cover all types of HPV and be given as a nasal spray. Researchers say they have created a synthetic vaccine that can be delivered as a nasal spray for HPV - source of the most common sexually transmitted disease in the United States and a cause of cervical cancer. The experimental vaccine, tested so far just with mice, also offers protection against different strains of HPV. The existing vaccine for HPV, called Gardasil, protects against four strains of the virus responsible for about 70% of all cervical cancers. It requires three injections for full protection. The advantages of the synthetic vaccine are that it can be synthesized as if it were a drug and, made chemically in the lab rather than having to use biological systems. A synthetic vaccine should also be cheaper. Using this approach, the vaccine could also be given nasally. In their experiments, Roden and his colleagues used a protein from one of the strains of HPV - HPV16 - to create a man-made vaccine in the laboratory. When the vaccine was given to mice by injection or as nasal spray, it protected not only against HPV16, but also against another strain of the virus -HPV45.

Steven Reinberg; New HPV Vaccine Promising in Mice. It might cover all types of HPV and be given as a nasal spray, researchers say, posted 4/15/08; health day; available on file:///E:/New%20HPV%20Vaccine%20Promising%20in%20Mice.htm

   Cross-Protection for HPV Types Not Covered By Vaccine Top

Impact of a quadrivalent HPV vaccine on infection and cervical disease related to 10 non-vaccine HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) associated with more than 20% of cervical cancers was evaluated. Vaccination reduced the rate of HPV-31/33/45/52/58 infection by 17.7% and of cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS) by 18.8%. Vaccination also reduced the rate of HPV-31/58/59-related CIN1-3/AIS by 26.0, 28.1, and 37.6%, respectively. Although a modest reduction in HPV-31/33/45/52/58-related CIN2 or worse was observed, the estimated reduction was not statistically significant. These cross-protection results complement the vaccine's prophylactic efficacy against diseases associated with HPV-6, -11, -16, and -18.

Wheeler et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic non vaccine HPV types in sexually active women aged 16-26 years; J Infect Dis. 2009 Apr 1;199(7):919-22. none

   Vaccine Effective for Older Women and Young Men: Studies Top

HPV infection typically occurs within a few years after a person becomes sexually active, so the vaccine is recommended at a young age. Gardasil is currently approved for girls and young women aged 9 to 26 years. Recent studies, however, indicate that the vaccine is also effective for older women and young men. As reported in the June 1, 2009 advance online edition of The Lancet, Nubia Muñoz from the National Institute of Cancer in Bogota, Columbia, and colleagues reported that the quadrivalent HPV vaccine is efficacious in women aged 24-45 years not infected with the relevant HPV types at enrolment. In men, anal-genital HPV infection can lead to genital warts and penile, perineal, perianal and anal neoplasia and cancer. In addition, male HPV infection contributes significantly to infection and subsequent cervical disease in women. The quadrivalent HPV vaccine is efficacious in reducing the burden of HPV 6/11/16/18-related external genital lesions and infection in young men aged 16-26 years naive to the relevant HPV type at baseline.

Studies Show HPV Vaccine Is Effective for Older Women and Young available from Men

   Editor's Note Top

Gardasil (Merck's cervical cancer vaccine) is the first vaccine against HPV to be awarded World Health Organization (WHO) prequalification. It is a recombinant quadrivalent vaccine against HPV types 6,11,16 and 18 responsible for 70% of cervical cancer and 90% of genital warts. It is currently indicated for use in girls and young women 9through 26 years of age for the prevention of cervical, vulvar and vaginal cancers and warts In July, 2009, WHO approved another cervical cancer vaccine Cervarix made by GlaxoSmithKline. It protects against HPV 16 and 18. Cervarix is formulated with AS04 , a proprietary adjuvant that boosts the immune system response for a longer period of time to HPV strains. In developing countries, HPV vaccination seems to be a distant dream due to high cost.


Print this article  Email this article
Previous article Next article


   Next article
   Previous article 
   Table of Contents
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (87 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

    New HPV Vaccine ...
    Vaccine Promisin...
    Vaccine Effectiv...
    Editor's Note

 Article Access Statistics
    PDF Downloaded299    
    Comments [Add]    

Recommend this journal